and 2-h PG values. The cut-off value, however, is too low in clinical practice because of its low positive predictive value [3] .
In the new ADA criteria, the FPG cut-off for diabetes is lowered from 7.8 to 7.0 mmol/l, and the new IFG level is set at 6.1 mmol/l. Comparing these new criteria with the WHO criteria using the 2-h glucose values in our group, we found that the concordance between subjects with IFG and IGT was low (Fig. 1) . Thus, the two tests diagnose two different populations of subjects with disturbed glucose metabolism. Number of subjects with impaired glucose metabolism classified according to the diagnostic criteria by the ADA (impaired fasting glucose, IFG, fasting plasma glucose ³ 6.1 mmol/l and < 7.0 mmol/l) or the WHO (impaired glucose tolerance, IGT, 2-h plasma glucose ³ 7.8 mmol/l and < 11.1 mmol/l). The shaded area includes subjects that fulfill both sets of diagnostic criteria Table 1 . Metabolic and anthropometric variables in women with impaired fasting glucose (IFG, fasting glucose ³ 6.1 mmol/l and < 7.0 mmol/l), impaired glucose tolerance (IGT, 2-h glucose ³ 7.8 mmol/l and < 11.1 mmol/l) or both. Data are shown as mean ± SD (Table 1 ) suggest, however, that the subjects with IGT (whom the new diagnostic criteria miss) and the subjects with IFG (whom were previously undiagnosed) are comparable in terms of body mass index, blood pressure and serum lipids. Hence, although constituting two groups with surprisingly little overlap, the subjects with IGT and IFG may exhibit similar risk for development of diabetes and cardiovascular disease. In the subjects with diabetes, there was also little agreement between the FPG and the 2-h PG.
We therefore want to draw attention to the fact that although the new FPG cut-off value has been lowered in the ADA criteria, there is a considerable discordance with the WHO diagnostic criteria for diabetes and impaired glucose tolerance, particularly from the point of view of the individual subject. Without making a statement as to which set of criteria is the best, we consider it to be of great importance to clinically follow the subjects with IFG or IGT to determine whether both diagnostic groups run a similar risk of developing diabetes.
Yours sincerely, H. Larsson, G. Berglund, F. Lindgärde, B. AhrØn
